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Adherence of uremic erythrocytes to vascular endothelium
decreases endothelial nitric oxide synthase expression.
Background. High prevalence of atherosclerotic cardio-
vascular events accounts for much of the mortality among
patients suffering from end-stage renal disease (ESRD).
Endothelial dysfunction as a pathogenic mechanism might con-
tribute to increasing the cardiovascular risk of ESRD. Reduced
endothelium-dependent vasodilation has consistently been ob-
served in chronic renal failure patients. Since nitric oxide (NO)
is the principal endothelium-derived vasodilator, a reduction in
the NO bioavailability may be envisaged in ESRD patients.
Methods. To clarify whether exposure to erythrocytes from
ESRD patients might modulate NO release by the endothelium,
we evaluated endothelial NO synthase (eNOS) protein levels
(Western blot), eNOS mRNA quantity (real-time PCR), and
NOS activity (conversion of L-[3H] arginine in L-[3H] citruline)
in endothelial cultures stimulated by erythrocytes from healthy
subjects and ESRD patients.
Results. A time-dependent decrease in eNOS protein levels
was evident in cultures treated with erythrocytes from ESRD
patients. This observation was consistent with the decreased
eNOS mRNA quantities induced by erythrocytes from such pa-
tients. Moreover, compared to controls, NOS activity exhibited
a significant reduction after incubation with erythrocytes from
ESRD patients. The observed eNOS reduction induced by ery-
trocytes from ESRD patients was totally abolished by annexin
V, able to mask red blood cell (RBC) surface-exposed phos-
phatidylserine.
Conclusion. These findings suggest that adhesion of erythro-
cytes from ESRD patients to vascular endothelium may cause
a decrease in the levels of eNOS mRNA and protein, and in-
hibition of NOS activity. This might contribute to endothelial
dysfunction, and may play a role in the pathogenesis of cardio-
vascular disease in ESRD patients.
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The vascular endothelium has long been thought to be
a single lining of the blood vessels but it is now recognized
to be a complex organ with paracrine, autocrine, and en-
docrine functions [1–3]. Healthy endothelium plays a piv-
otal role in the maintenance of vascular homeostasis and
in the prevention of atherosclerosis [4]. Many of the favor-
able and antiatherogenic effects of intact endothelium are
exerted by nitric oxide. NO is continuously synthesized
from L-arginine in the endothelial cells by constitutive
eNOS activity [5]. NO is a potent vasorelaxing substance
that regulates vascular tone and vasomotor function [6, 7].
In addition, NO inhibits platelet aggregation [8], leuko-
cyte adhesion to the endothelium [9], and vascular muscle
cell proliferation [10], all key events involved throughout
the course of atherosclerosis [3].
Patients suffering from end-stage renal disease
(ESRD) experience accelerated atherosclerosis [11], and
the high prevalence of atherosclerotic cardiovascular
events accounts for much of the morbidity and mortality
in this patient population [12]. Perturbations of the en-
dothelial physiology (endothelial dysfunction) might be
a pathogenic mechanism contributing to the markedly
increased cardiovascular risk of ESRD [13]. Reduced
endothelium-dependent vasodilation and raised plasma
levels of endothelium-derived mediators have consis-
tently been observed in chronic renal failure patients
[14–18]. Since NO is the principal endothelium-derived
vasodilator, the finding of attenuated endothelium-
dependent vasodilation suggests a reduction in the NO
bioavailability in chronic uremic patients [14–16]. The
mechanisms of reduced NO bioactivity in renal failure
remain unclear, however.
Defective eNOS is thought to be a crucial parame-
ter characterizing endothelial cell dysfunction [19]. De-
creased eNOS mRNA and protein levels and inhibition
of NOS activity have been shown to occur following the
adhesion of sickle erythrocytes to the vascular endothe-
lium [abstract; Phelan et al, Blood 86(Suppl 1):418a, 1995]
[20, 21]. Erythrocyte-endothelial interaction is especially
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Table 1. Demographic and clinical characteristics of the study
population
Control Hemodialysis
(N = 12) (N = 12) P value
Male 6 7 NS
Smoker 1 1 NS
Age years 57 ± 7.5 61.6 ± 10.4 0.225
Systolic blood pressure mmHg 125.4 ± 10.7 123.2 ± 16 0.712
Diastolic blood pressure mmHg 77 ± 7.2 76.7 ± 10 0.927
Total cholesterol mg/dL 165.7 ± 33.5 167 ± 39.6 0.930
Triglycerides mg/dL 131.3 ± 34 161 ± 99.8 0.341
Haemoglobin g/dL 14.3 ± 1.3 11.1 ± 1.6 <0.001
Creatinine mg/dL 1 ± 0.1 9.7 ± 2 <0.001
Body mass index 24.4 ± 1.2 24 ± 1.9 0.547
pronounced in sickle cell disease, and may be relevant
to reported vascular damage [22]. In both renal failure
patients and experimental models in vivo, there is some
evidence of a reduced expression of endothelial NOS and
a resultant deficiency of NO [23]. Because red blood cells
from patients on hemodialysis have an increased propen-
sity to adhere to human endothelial cells through surface-
exposed phosphatidylserine [24], it is possible that
increased adhesiveness to vascular endothelium of ure-
mic erythrocytes might affect the endothelial NO syn-
thetic pathway. In the present study, we examined the
effect of uremic erythrocytes on the expression and the




Red blood cells (RBC) were obtained from ESRD pa-
tients on chronic maintenance hemodialysis and from
healthy control subjects. Table 1 shows the main clini-
cal and biochemical characteristics of the participants.
ESRD patients had been on regular dialysis treatment
for more than 6 months (mean time on dialysis 47 ±
38 months), and were recruited from among those pre-
senting at the dialysis center of the University of Chieti.
The cause of ESRD was chronic glomerulonephritis in 6
patients, chronic interstitial nephritis in 4, and nephroan-
giosclerosis in 2. Exclusion criteria included age younger
than 18 years or older than 75 years, diabetes mellitus,
uncontrolled hypertension, active infection, malignant or
inflammatory disease, blood transfusion over the past 3
months, and iron and folic acid deficiency. All patients
were on a stabilized erythropoietin dosage, and were un-
dergoing dialysis 3 times weekly with a 4-hour dialysis
session using bicarbonate dialysate and first-use synthetic
membranes (polysulphone, N = 7; polyacrylonitrile, N =
5). Healthy control subjects enrolled in the study were not
receiving any medication. Subjects with any abnormali-
ties on routine physical examination, standard laboratory
tests, ECG, or chest x-ray were not included in the study.
Written informed consent was obtained from all taking
part in the study.
Materials
Phosphate-buffered saline (PBS), glutamine, fetal calf
serum (FCS), and trypsin were from Mascia Brunelli
(Milan, Italy); heparin, collagenase, gelatin, endothelial
cell grown factor (ECGF), HEPES, EDTA, NADPH,
Nonident P-40, sodium deoxycholate, SDS, L-NAME,
CaCl2, and BH4 were from Sigma Chemical Co.
(St. Louis, MO, USA); ionomycin from Boeringher
Mannheim (Mannheim, Germany), M199 medium
from Biospa (Milan, Italy); and DMEM/F12 from
Gibco BRL (Grand Island, NY, USA). Fluorescein
isothiocyanate-labeled annexin V (FITC-AnV) was
from Bender MedSystems (San Bruno, CA, USA).
Heavy- and light-chain specific (goat) peroxidase was
from Calbiochem (San Diego, CA, USA), 4–12% Nu-
PAGE Novex Pre-Cast gel system was from Invitro-
gen (Carlsbad, CA, USA). Hybond ECL nitrocellulose
membranes and Enhanced Chemiluminescent (ECL)
was from Amersham Pharmacia Biotec (Bucks, Eng-
land). Bio-Rad Image Processing and Analysis System
was from Bio-Rad (Hercules, CA, USA). [3H] argi-
nine monohydrocloride 30 to 60 Ci/mmol was from
Perkin Elmer (Boston, MA, USA). Resin DOWEX
AGWX8-200 was provided by Aldrich (Steinheim,
Germany). All chemicals for real-time polymerase chain
reaction (PCR) were from Applied Biosystems (Foster
City, CA, USA).
Antibodies: mouse monoclonal anti-b-actin (1:10000)
was from Sigma; mouse monoclonal anti-eNOS (1:2500)
was from BD Transduction Lab (Lexington, KY, USA);
and antimouse IgG (1:10,000) was provided by Cal-
biochem.
Preparation of cells
Erythrocytes. Blood was drawn by venipuncture into
evacuated tubes containing EDTA. After centrifugation
at 700 g for 5 minutes at 4◦C, the plasma and buffy coat
were removed, the RBC pellet was washed 3 times with
PBS to remove traces of serum, and then resuspended to
0.5% hematocrit in DMEM/F12 with 0.1% of FCS.
Endothelial cells. Umbilical cords were obtained
from randomly selected healthy mothers giving birth at
Chieti University Hospital. Primary cultures of human
umbilical vein endothelial cells (HUVEC) were obtained
as previously described [25]. After perfusion of umbili-
cal cords with 0.1% collagenase at 37◦C, HUVEC were
grown on 0.2% gelatin-coated tissue culture plates in
M199 endothelial growth medium supplemented with
20% FCS, 10 lg/mL heparin, and 50 lg/mL ECGF (com-
plete medium). In all experiments cells were used be-
tween the 3rd and 6th passage in vitro.
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Experimental protocol
Endothelial cells (EC) were plated (3.5 × 105 cells
mL−1) in Petri dishes (100 mm2) or 6-well plates in
complete M199 endothelial growth medium, and grown
to confluence. After 72 hours, the EC monolayer was
washed twice with PBS to remove traces of serum, and
incubated for 3, 6, 18, and 24 hours with DMEM/F12 with
0.1% of FCS (basal), in the presence or absence of red
blood cells (RBC 0.5%) from healthy controls (control)
or from patients with end-stage renal disease (ESRD).
In another set of experiments, RBC suspensions
from uremic patients (obtained after centrifugation as
described above) were incubated for 5 minutes with
FITC-AnV (100 nmol/L) to mask RBC surface-exposed
phosphatidylserine (PS) [24] before they were added to
HUVEC monolayers.
eNOS Western blot analysis
As described in the experimental protocol, HUVECs
were first stimulated and then lysed in lysis buffer contain-
ing PBS, 1% Nonident P-40, 0.5% sodium deoxycholate,
0.1% SDS, and 4% protease inhibitor cocktails. Protein
concentrations in the cell lysates were measured by spec-
trophotometric assay (Bradford protein assay; Bio-Rad).
Equal amounts of protein (30 lg) were analyzed by West-
ern blot (WB) with 4–12% NuPAGE Novex Pre-Cast gel
system (Invitrogen). The nitrocellulose membranes were
then blotted in TBS-milk and incubated overnight with
mouse monoclonal anti-b-actin or mouse monoclonal
anti-eNOS. The nitrocellulose membranes were washed
in TBS-Tween 20 (0.1%, v/v), and incubated with anti-
mouse IgG for 2 hours. After further washing with TBS,
blots were developed using ECL, and quantified using a
computerized densitometric system (Bio-Rad Image Pro-
cessing and Analysis System; Bio-Rad).
eNOS mRNA quantification by real-time PCR
RNA preparation. Total RNA was extracted from
the HUVEC using NucleoSpin RNAII (Macherey-Nagel
GmbH & Co., Duren, Germany).
RT reaction. Two micrograms total RNA was em-
ployed to synthesize of first strand cDNA using the High-
Capacity cDNA Archive Kit (PE Applied Biosystems,
Foster City, CA, USA).
Real-Time PCR. A single-tube real-time PCR assay
was optimized for the quantization of e-NOS gene ex-
pression versus GAPDH or 18s rRNA (“housekeeping”
genes) with specific primers and probes using TaqManTM
technology on an ABI Prism 9700HT Sequence Detec-
tion System Instrument (Applied Biosystems) connected
to Sequence Detector Software (SDS version 2.0; Ap-
plied Biosystems) for collection and analysis of data.
According to the recommendations of the manufac-
turer, 25 lL reactions were performed in a MicroAmp
Optical 96-well reaction plate using 12.5 mL TaqMan
Universal PCR Master Mix 2X, 1.25 mL Assay-on-
DemandTM Gene Expression Product 20X for e-NOS
target genes (TaqMan MGB probe, FAMTM dye-labeled;
Applied Biosystems), and 1.25 mL Pre-Developed Taq-
Man Assay Reagent 20X for GAPDH reference genes
(TaqMan MGB probe, VICTM dye-labeled). For each
sample, 5 lL of the cDNA reaction mix, corresponding
to 200 ng of RNA transcript, was added.
PCR was performed at 50◦C for 2 minutes and at 95◦C
for 10 minutes, and then run for 45 cycles at 95◦C for 15
seconds and at 60◦C for 1 minute. Each sample was tested
in triplicate and repeated twice. The means of Ct values
calculated by SDS Software for e-NOS and GAPDH in
each reaction well were used for further calculations.
For each sample, the fold decrease in e-NOS gene ex-
pression after RBC incubation was evaluated with 2−DDCt
according to the comparative Ct method, where DDCt
was the normalized mean Ct value of untreated cells −
the normalized mean Ct value of treated cells. For valida-
tion of the comparative Ct method, a relative efficiency
plot e-NOS/GAPDH was evaluated.
Nitric oxide synthase (NOS) activity
HUVEC grown to confluence in 100-mm diameter
Petri dishes were stimulated by RBC from healthy sub-
jects or RBC from ESRD patients and, as a positive
control, by ionomycin (2 lmol/L) for 18 and 24 hours.
After incubation, cells were detached by trypsin/EDTA
(0.05/0.02% v/v), washed with PBS, then resuspended
in 1 mL of reaction buffer (HEPES 20 mmol/L, EDTA
0.5 mmol/L, dithiothreitol 1 mmol/L, pH 7.2) and soni-
cated on ice with 3 10-second bursts. In each test tube,
the following reagents were added to 100 lL lysate at
the final concentrations: 2 mmol/L NADPH, 1.5 mmol/L
CaCl2, 0.1 mmol/L BH4 (tetrahydrobiopterin), 2.5 lCi L-
[3H]arginine = (0.4 lmol/L) [26, 27]. After a 15-minute
incubation at 37◦C, the reaction was stopped by adding
2 mL HEPES-Na pH 6 containing 2 mmol/L EDTA; the
entire reaction mixture was applied to 2-mL columns
of Dowex AG50WX-8 (Na+ form) and eluted with
4 mL of water. The radioactivity corresponding to the
[3H]citrulline content in the eluate was measured by a
liquid scintillation analyzer (Packard Bio Science Com-
pany, Meriden, CT, USA). NOS activity was expressed as
pmol citrulline/min/mg cell protein. In some experiments,
L-NAME (1 mmol/L) was added 40 minutes before
adding L-[3H]arginine.
Statistical analysis
Results are presented as mean ± SD. For comparison
of data, analysis of variance (ANOVA) test followed by
Bonferroni’s analysis was used. Significance was defined
as a P value less than.05.
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Fig. 1. Representative protein blotting of
eNOS and b-actin after 3 hours (A), 6 hours
(B), 18 hours (C), and 24 hours (D) of HU-
VEC stimulation with basal medium ( , B),
RBC from healthy controls ( , C1, C2), or
RBC from ESRD patients ( , P1, P2, P3). Sig-
nals of eNOS were quantified and normalized
to those of b-actin using a bioimaging ana-
lyzer.
RESULTS
In a recent study [24] we demonstrated an enhanced
adherence of human uremic erytrocytes to human en-
dothelial cells in culture, possibly via a direct interaction
between matrix thrombospondin and increased RBC PS
exposure that may serve as a recognition site for the
HUVEC monolayers. To clarify whether the increased
adherence of washed erythrocytes from ESRD patients
might potentially contribute to endothelial dysfunction in
uremia, we first evaluated eNOS protein levels (by West-
ern blotting analysis) in HUVEC stimulated with RBC
from control and ESRD subjects.
Subsequently, to better understand the possibility of
a transcriptional regulatory role being played by RBC
from control and ESRD subjects in eNOS synthesis, we
also quantified eNOS mRNA by real-time PCR. Because
increased PS exposure might play its part in the regula-
tion of endothelial NO release mechanisms, we evaluated
both eNOS protein and mRNA levels in HUVEC stimu-
lated with erythrocytes from patients in presence or ab-
sence of FITC-AnV, used to mask RBC surface-exposed
PS.
Next, in the same experimental conditions, the impact
of incubation with RBC (control and ESRD) on NOS
activity was also examined. To this end we monitored the
conversion of L-[3H] arginine into L-[3H] citrulline.
When the effect of washed RBC (control and ESRD)
on eNOS protein levels was followed-up for 24 hours, a
distinct time-dependent effect was observed. As shown
in representative examples in Figure 1, RBC from ESRD
patients (as compared to both basal and control condi-
tions) caused a significant reduction in the eNOS level.
Automated image analysis enabled the band intensity of
all the samples to be quantified: after 18 and 24 hours,
the mean densitometric intensity in samples stimulated
by RBC from ESRD patients was, respectively, almost 1.7
and 3 lower than the band intensity in samples stimulated
by control RBC (Fig. 2). Furthermore, our data demon-
strate that, as compared to endothelial cells treated with
RBC from ESRD patients, the addition of AnV (100
nmol/L) to RBC suspensions induced, after both 18 and
24 hours of incubation, a significant increase in eNOS
protein levels, which reached those observed at basal con-
ditions (Fig. 3).
We next evaluated the ability of RBC (control and
ESRD) to modulate the eNOS mRNA quantity in
HUVEC cultures (Fig. 4). After 24 hours of incubation,
as compared with cells exposed to RBC from control sub-
jects, RBC from ESRD patients slightly but significantly
decreased eNOS mRNA quantity. This inhibitory effect
on eNOS mRNA levels by uremic erythrocytes was to-
tally abolished by RBC preincubation with AnV (Fig. 4).
We also examined the effect of RBC (control and ESRD)
on eNOS mRNA levels after longer time incubation
than 24 hours. After 48 hours of stimulation with RBC
from ESRD patients, eNOS mRNA quantity significantly
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Fig. 2. Time effect of basal medium ( ), RBC
from controls ( , N = 12) or RBC from ESRD
patients ( , N = 12) on eNOS levels in HU-
VEC cultures. Signals of eNOS were quanti-
fied and normalized to those of b-actin using a
bioimaging analyzer. Results are mean ± SD
values of three experiments. ∗P < 0.05, #P <
0.05 vs. Basal 18 hours; ◦P < 0.05 vs. Control
18 hours; §P < 0.05 vs. Basal 24 hours; †P <





























































Fig. 3. Effect of RBC preincubation with annexin V (AnV) on eNOS protein levels. RBC from ESRD patients ( , N = 12), RBC from ESRD
patients ( AnV ( , N = 12) after 18 hours (A) or 24 hours (B) of HUVEC stimulation. ∗ P < 0.05 vs. ESRD 18 hours, ◦P < 0.05 vs. ESRD 24 hours.
decreased compared to control (0.47 ± 0.05 and 0.31 ±
0.01 mRNA eNOS quantity, control-RBC and ESRD-
RBC, respectively; P < 0.05).
The impact of RBC (control and ESRD) on NOS ac-
tivity was also examined (Fig. 5). Compared with en-
dothelial cells exposed to basal medium (basal), after 24
hours of incubation, RBC from healthy controls signifi-
cantly increased eNOS activity (0.37 ± 0.03 vs. 0.19 ± 0.03
pmol/min/mg total protein, P < 0.05). On the contrary, af-
ter 18 and 24 hours of incubation, no difference between
endothelial cells exposed to RBC from ESRD patients or
basal medium could be detected in terms of NOS activity.
Again, compared to controls, NOS activity showed a re-
duction after 18 hours that became significant at 24 hours
of HUVEC incubation with RBC from ESRD patients
(0.23 ± 0.02 and 0.16 ± 0.01 vs. 0.29 ± 0.03 and 0.37 ±
0.03 pmol/min/mg total protein, 18 and 24 hours, respec-
tively; P < 0.05 at 24 hours). When HUVEC cultures
were exposed to ionomycin (a molecule that induces NO
production via mobilization of intracellular Ca2+) in or-
der to assess the integrity of the eNOS activation system,
cells exhibited a significant increase in NO production
(P < 0.05). Preincubation with L-NAME (which causes a
selective inhibition of NOS activity) caused a significant
inhibition in stimulated NOS activity (P < 0.05).
DISCUSSION
Several studies indicate that in patients suffering from
ESRD NO production is reduced [28]. Given the impor-
tant role of NO in maintaining vascular function and in-
tegrity, deficient NO production may be one of the key
steps leading to the functional and structural vascular
changes in renal failure. The present study focuses on the



























Fig. 4. Effect of RBC from controls ( , N = 12), RBC from ESRD
patients ( , N = 12), or RBC from ESRD patients preincubated with
AnV ( , N = 12) on eNOS mRNA quantity in HUVEC cultures by real-
time PCR analysis. Data of eNOS gene expression were normalized
versus GAPDH gene expression. Results are mean ± SD values of
three experiments. ∗P < 0.05 vs. Control and vs. ESRD + AnV.
ESRD erythrocyte adherence effects on eNOS expres-
sion and activity in cultured HUVEC, since decreased
eNOS expression and a resultant deficiency of NO might
be one of the conjectural mechanisms leading to endothe-
lial dysfunction in ESRD [14].
Our study demonstrated that, in cultured HUVEC,
erythrocytes from patients with ESRD inhibited the
eNOS expression, activity and, consequently, NO pro-
duction, whereas erythrocytes from healthy subjects had
no such role. This inhibitory effect can be attributed to in-
creased exposure of membrane PS in RBC from ESRD
patients, as demonstrated by AnV preincubation effect
on eNOS level in our cellular model. Since our observa-
tions, along with others [28], support the hypothesis of re-
duced NO production in ESRD patients. Regarding the
possible role of comorbidities/medications in the inter-
actions between erythrocytes and the endothelium, our
patients were not affected by morbidities or treated with
drugs known to influence adherence of RBC to endothe-
lium, potentially impairing NO production. This supports
the hypothesis of an essential role of uremia in increased
erythrocyte adherence to endothelium and consequent
potential down-regulation of NO synthesis in ESRD pa-
tients.
On the other hand, several reports indicate that the
NO bioavailability is reduced in ESRD [16]. Recently,
much attention has in fact been paid to the evidence that
reduction in NO bioavailability, which can be explained
not only by a mechanism of NO inactivation but also by
a reduced NO release, may have a crucial role in the loss
of endothelial function [29]. Nitric oxide can be inacti-
vated by the superoxide radicals (O2−) [30], and a variety
of pathologic conditions, including chronic renal failure
[31], can be associated with the presence of increased
O2− plasmatic levels. NO and O2− can easily react to
produce peroxynitrite, a potent long-living oxidant [30],
as demonstrated by the presence of nitrotyrosine in bi-
ological fluids such as plasma and urine of patients with
chronic renal failure.
This hypothesis does not eliminate the possibility that
in these patients might coexist both reduced NO release
and reduced bioavailability.
However, some studies have also demonstrated an in-
creased NO release in ESRD patients [32]. This suggests
that in this pathologic condition, in spite of possible in-
creased NO synthesis, NO availability was not increased
and, indeed, very likely reduced. For, as mentioned above
[29], in pro-oxidant conditions, a great amount of NO can
be rapidly converted into peroxynitrite [32].
Thus, the finding of reduced NO bioavailability, as
demonstrated by functional studies, does not provide in-
sight into the mechanisms causing endothelial dysfunc-
tion, because reduced bioavailability can be a result of
decreased NO production, increased NO degradation, or
both.
Our results and several others indicate that in uremia
NO production might be reduced [33, 34]. In such patients
this may occur by a variety of mechanisms, among which
may be included reduced activity of NOS secondary to de-
ficiency of substrate (L-arginine) or critical cofactors for
NO synthesis (tetrahydrobiopterin), or inhibition of NOS
by endogenous inhibitors accumulating in renal failure,
such as asymmetrical dimethylarginine (ADMA) [34].
However, it appears that there is no evidence of any sub-
strate deficiency in NOS in uremia [16]. Furthermore,
the physiologic significance of ADMA accumulation in
ESRD patients still needs to be definitively established
[13].
Since ESRD is associated with accelerated atheroscle-
rosis, it seems reasonable to assume that a circulating
“uremic factor” could be responsible for these changes.
The vascular endothelium is a likely target for the actions
of circulating elements, such us modified RBC and/or
plasmatic factors. However, previous cell culture stud-
ies did not unequivocally show that uremic plasma fac-
tors only affect the eNOS activity in endothelial cell lines
[35–37]. As matter of fact, Jankowski et al have recently
demonstrated that the eNOS activity was unaffected by
accumulation of plasmatic phenylacetic acid in ESRD pa-
tients [38].
In our recent paper, supporting the hypothesis of
RBC involvement in vascular complication of uremia,
we have shown [24] that PS externalization may pro-
mote increased uremic erythrocyte adhesion to cultured
endothelial cells, and we surmised that this might con-
tribute to endothelial dysfunction in ESRD through an
inhibitory effect on eNOS expression and activity. The





















































Fig. 5. Effect of RBC from controls (N =
12) or RBC from ESRD patients (N = 12)
on NOS activity at 18 hours and 24 hours.
Results are mean ± SD values of three ex-
periments.
∗
P < 0.05 vs. basal 24 hours,
#P < 0.05 vs. control 24 hours, †P < 0.05 vs.
ionomycin 24 hours.
present study may offer one explanation of the decreased
NO production in patients with ESRD because erythro-
cytes from patients inhibited eNOS expression and activ-
ity in cultured HUVEC.
The mechanism whereby ERSD erythrocytes can reg-
ulate gene expression in the endothelium is under inves-
tigation. The membrane lipids of uremic red blood cells
have been shown to change quantitatively and qualita-
tively [24, 39], and lipids are widely used in nature as
second messengers in pathways leading to gene induc-
tion. Recently, it has been shown that PS-liposomes in-
hibit NO production upstream of the transcription of
inducible NO synthase (iNOS) mRNA, and that the in-
hibition of p38MAP kinase is crucial for this effect [40].
To investigate the interactions of the eNOS enzyme with
phospholipids present in membrane and the functional
consequences of these interactions on enzyme catalytic
activity, Venema et al [41] have shown that binding of
eNOS to PS vesicles prevents the subsequent binding
of the enzyme to calmodulin, leading to inhibition of
eNOS catalytic activity. In this regard, we evaluated both
eNOS protein and mRNA levels in HUVEC stimulated
with RBC from patients in presence or absence of an-
nexin V, which has a propensity for binding to the PS
domain, rendering it unavailable for other biological pro-
cesses [24]. Preincubation with FITC-AnV totally abol-
ished the ESRD-RBC inhibitory effect on eNOS levels
(both protein and mRNA), supporting the idea that the
observed decreased NO production might be mediated
by increased exposure of PS on the membrane of uremic
red cells.
The hypothetical defective activity of eNOS in ESRD,
as also suggested by our study, might have several conse-
quences. Reduced NO production, given the key role of
NO in maintaining vascular function and integrity, may
represent one crucial step leading to the functional and
structural vascular changes encountered in uremia, and
may, thus, be implicated in the pathogenesis of uremic
vasculopathy. In addition, chronic NOS inhibition might
have secondary effects, such as increased expression of
adhesive molecules and oxidative stress, resulting in en-
dothelial damage and accelerated atherosclerosis [42].
Inhibition of eNOS may also play a causal role in the
increased peripheral resistance and elevated blood pres-
sure in ESRD [37]. Finally, the endogenous inhibitory
action of uremic RBC on eNOS may be implicated in
the altered biology of endothelial progenitor cells (EPCs)
observed in uremia [43]. EPCs are mobilized from bone
marrow under various stimuli, and are critical for neovas-
cularization and angiogenesis [44]. Because eNOS has an
essential role in the mobilization of EPC [45], deficient
NO production might lead to decreased mobilization of
EPCs from bone marrow [43].
CONCLUSION
Our data demonstrate that adhesion of uremic RBC to
endothelial cells in culture may cause a decrease in the
levels of eNOS mRNA and protein, potentially due to
an increased exposure of membrane PS, and inhibition
of NOS activity. This mechanism may contribute to in-
creased atherosclerosis and cardiovascular morbidity in
ESRD patients.
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